Status:
RECRUITING
3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension
Lead Sponsor:
Shengjing Hospital
Collaborating Sponsors:
Zhongda Hospital
Conditions:
Cirrhosis, Liver
Portal Hypertension
Eligibility:
All Genders
18-75 years
Brief Summary
How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hyp...
Detailed Description
China suffers the heaviest burden of liver disease in the world. The number of chronic liver disease is more than 400 million. Either viral-related hepatitis, alcoholic hepatitis, or metabolic-related...
Eligibility Criteria
Inclusion criteria were: (1) ≥18 years; (2) written informed consent; (3) confirmed ACLD of any liver disease etiology; (4) clinically indicated for HVPG measurement, with 3D-MRE performed within one month prior.
Exclusion criteria were: (1) hepatic or extrahepatic malignancies, or large hepatic or splenic focal diseases affecting MRE measurement; (2) MR or HVPG contraindications; (3) prior liver or splenic surgery affecting MRE measurement; (4) treatment with nonselective β-blockers (NSBB) between MRE and HVPG measurements; (5) invalid or unreliable HVPG or MRE results and (6) biliary obstruction or dilation on MR images.
Key Trial Info
Start Date :
August 16 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05475015
Start Date
August 16 2022
End Date
December 1 2026
Last Update
February 9 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shengjing Hospital
Shenyang, Liaoning, China, 210000